Literature DB >> 1499908

Successful dissolution of cholesterol gallstone during treatment with pravastatin.

J W Smit1, K J van Erpecum, M F Stolk, R A Geerdink, O J Cluysenaer, D W Erkelens, G P van Berge Henegouwen.   

Abstract

This case report describes a 51-year-old hypercholesterolemic male patient who had a large solitary cholesterol gallstone. The patient was treated with the 3-hydroxy 3-methylglutaryl coenzyme A (HMG-CoA) reductase inhibitor pravastatin, 40 mg/day. After 3 months of therapy, serum cholesterol level normalized (7.7 mmol/L before and 5.2 mmol/L during treatment), and biliary cholesterol saturation index decreased from 1.3 before to 0.8 during treatment. Repeatedly performed ultrasonography showed complete gallstone dissolution. Pravastatin may be valuable in the nonsurgical treatment of cholesterol gallstone disease particularly when there is an additional indication for HMG-CoA reductase inhibitors because of hypercholesterolemia.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1499908     DOI: 10.1016/0016-5085(92)90045-z

Source DB:  PubMed          Journal:  Gastroenterology        ISSN: 0016-5085            Impact factor:   22.682


  10 in total

1.  Role of fibrates and HMG-CoA reductase inhibitors in gallstone formation: epidemiological study in an unselected population.

Authors:  F X Caroli-Bosc; P Le Gall; P Pugliese; B Delabre; C Caroli-Bosc; J F Demarquay; J P Delmont; P Rampal; J C Montet
Journal:  Dig Dis Sci       Date:  2001-03       Impact factor: 3.199

Review 2.  Prevention of cholesterol gallstones by inhibiting hepatic biosynthesis and intestinal absorption of cholesterol.

Authors:  Helen H Wang; Piero Portincasa; Ornella de Bari; Kristina J Liu; Gabriella Garruti; Brent A Neuschwander-Tetri; David Q-H Wang
Journal:  Eur J Clin Invest       Date:  2013-02-19       Impact factor: 4.686

3.  Serum Plant Sterols Associate with Gallstone Disease Independent of Weight Loss and Non-Alcoholic Fatty Liver Disease.

Authors:  Pirjo Käkelä; Ville Männistö; Imre Ilves; Maija Vaittinen; Milla-Maria Tauriainen; Matti Eskelinen; Helena Gylling; Hannu Paajanen; Jussi Pihlajamäki
Journal:  Obes Surg       Date:  2017-05       Impact factor: 4.129

4.  Dissolution of gallstones with simvastatin, an HMG CoA reductase inhibitor.

Authors:  B A Chapman; M J Burt; R J Chisholm; R B Allan; K H Yeo; A G Ross
Journal:  Dig Dis Sci       Date:  1998-02       Impact factor: 3.199

Review 5.  Pravastatin. A reappraisal of its pharmacological properties and clinical effectiveness in the management of coronary heart disease.

Authors:  M Haria; D McTavish
Journal:  Drugs       Date:  1997-02       Impact factor: 9.546

Review 6.  Why laparoscopic cholecystectomy today?

Authors:  J Sandor; A Sandor; A Zaborszky; S Megyaszai; G Benedek; Z Szeberin
Journal:  Surg Today       Date:  1996       Impact factor: 2.549

7.  Effects of lovastatin and dietary cholesterol on sterol homeostasis in healthy human subjects.

Authors:  W C Duane
Journal:  J Clin Invest       Date:  1993-08       Impact factor: 14.808

8.  HMG-CoA reductase inhibitors (statins) activate expression of PPARalpha/PPARgamma and ABCA1 in cultured gallbladder epithelial cells.

Authors:  Jin Lee; Eun Mi Hong; Dong Hee Koh; Min Ho Choi; Hyun Joo Jang; Sea Hyub Kae; Ho Soon Choi
Journal:  Dig Dis Sci       Date:  2009-02-19       Impact factor: 3.199

9.  Effects of simvastatin and cholestyramine on bile lipid composition and gall bladder motility in patients with hypercholesterolaemia.

Authors:  J W Smit; K J Van Erpecum; P Portincasa; W Renooij; D W Erkelens; G P Van Berge-Henegouwen
Journal:  Gut       Date:  1995-11       Impact factor: 23.059

10.  Statin use and the risk of cholecystectomy in women.

Authors:  Chung-Jyi Tsai; Michael F Leitzmann; Walter C Willett; Edward L Giovannucci
Journal:  Gastroenterology       Date:  2009-01-24       Impact factor: 22.682

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.